Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

The inflammatory Bowel diseases (IBDs) are a chronic, relapsing inflammatory diseases of the gastrointestinal tract with heterogeneous behavior and prognosis. The introduction of biological therapies including anti-TNF, anti-IL-12/23, and anti-integrins, has revolutionized the treatment of IBD, but...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Tamara Pérez-Jeldres, Christopher J. Tyler, Joshua D. Boyer, Thangaraj Karuppuchamy, Andrés Yarur, Daniel A. Giles, Shaila Yeasmin, Luke Lundborg, William J. Sandborn, Derek R. Patel, Jesús Rivera-Nieves
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2019-03-01
Cyfres:Frontiers in Pharmacology
Pynciau:
IBD
small molecules
JAK inhibitors
S1P agonists
MOA
Mynediad Ar-lein:https://www.frontiersin.org/article/10.3389/fphar.2019.00212/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg